2nd International Conference on Tumor Progression & Therapeutic Resistance (TPTR)

Venue: Boston Marriott Burlington

Location: Burlington, Massachusetts, United States

Event Date/Time: Sep 18, 2005 End Date/Time: Sep 20, 2005
Registration Date: Sep 18, 2005
Early Registration Date: Aug 18, 2004
Abstract Submission Date: Aug 18, 2005
Paper Submission Date: Aug 18, 2005
Report as Spam


Dear Colleagues:

We have organized the second International Meeting on Tumor Progression and Therapeutic Resistance being held in Boston (at the Boston Marriott, Burlington) between September 18 - 20, 2005 (Sunday - Tuesday). The first International conference held in Philadelphia last November 7-9, 2004 attracted over 250 participants and was by all accounts successful. A report of the 1st International TPTR meeting is in press (Cancer Research, June 1, 2005) and a volume is being published by the New York Academy of Sciences.

A great deal of knowledge is unraveling complex molecular and cellular changes associated with malignant tumor progression. With this come opportunities for therapeutic development. Featuring the latest tools, models, and research findings the 2nd TPTR conference is a great opportunity to learn and develop new approaches and collaborations. We invite members of both academia and industry to attend the meeting and participate in the discussions.

Robert A. Weinberg (MIT) will deliver the Keynote address at this year's conference on mechanisms of formation of human tumor cells.

Sessions for the 2nd TPTR conference include:

Critical events in tumor progression
Tumor microenvironment, inflammation and stem cells
Mechanisms of therapeutic resistance
Pre-clinical models of human cancer
Technologies for drug discovery and pre-clinical validation
Molecular targets for therapy
Imaging, therapeutics, and metastasis targeting
Cellular damage and repair signaling
New drugs and combinations in pre-clinical or clinical testing

In addition to Bob Weinberg, other confirmed speakers include Joanne Brugge (Harvard), Mien-Chie Hung (MD Anderson Cancer Center), Rakesh Jain (Harvard), Mary Hendrix (Northwestern Univ.), Kornelia Polyak (Dana Farber), William Pao (Memorial Sloan Kettering Cancer Center), Gerry Melino (University of Rome), Alan Diehl (University of Pennsylvania), Gerard Evan (UCSF), Arul Chinnayan (University of Michigan), Eileen White (Rutgers), Scott Kern (Johns Hopkins), Peter Jones (USC), Ken Pienta (University of Michigan), Martin Brown (Stanford), Arnold Levine (Institute for Advanced Studies), Prem Reddy (Temple), Michael Andreef (MD Anderson Cancer Center), Bruce Zetter (Children’s Hospital of Boston), Gary Kelloff (National Cancer Institute), Stephen Eck (Pfizer), Michael Karin (UCSD).

The program also includes less formal poster sessions, social events, and a session on NIH funding. This year Bruce Zetter (Children's Hospital, Boston) will moderate the NIH funding session to focus on how individuals or teams can use innovative strategies to leverage and/or increase resources in the face of shrinking research funding.

So, put Boston on your calendar for Sunday through Tuesday September 18th to the 20th of 2005 and come join us for what looks like an outstanding meeting. Please bring this meeting to the attention of your colleagues, post-doctoral fellows and students who may benefit from attending this meeting. Please register early and submit an abstract. As we did last year a number of oral presentations will be selected from the submitted abstracts and a number of awards will be made for outstanding poster presentations.

Come to Boston earlier or stay later and enjoy the many historic and cultural delights the city has to offer. I look forward to welcoming you to the second annual International Conference on Tumor Progression and Therapeutic Resistance in September in Boston.


Wafik S. El-Deiry, M.D. Ph.D.
Conference Chairperson